ViaCyte, Inc. is focused on two key technology platforms which work together to address the need for an unlimited supply of specialized human cells to treat Diabetes. They are:

• Stem Cell Engineering
  Directed differentiation of human embryonic stem cells (hESCs) to generate therapeutic cell types

• Cell Encapsulation
  Proprietary encapsulation technology protects transplanted cells from the immune system, overcoming the need for long-term immunosuppression